Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Glioblastoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 115 for your search:
Start Over
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 22 and over
Trial IDs: EF-19, NCI-2013-00553, NCT01756729
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
A Study of the Efficacy and Safety of Nivolumab Versus Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
O6-Benzylguanine-Mediated Tumor Sensitization with Chemoprotected Autologous Stem Cell in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SCRI CNS 13, NCI-2015-00813, NCT01349660
Genetically Modified T Cells in Treating Patients with Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0266, NCI-2013-01508, 110266, 1103-1095, P11810, RD-11-III-06, NCT01454596
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: IRB# 55264, NCI-2012-01118, HCI55264, NCT01580969
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 1149367, 1-874640-1, 193831, 20141749, HSC20140450X, NCI-2014-00412, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Carboxyamidotriazole Orotate with or without Lomustine in Treating Patients with Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00047969, NCI-2014-00304, NCT01989052
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG221-C-003, NCI-2015-01170, NCT02273739
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Radiation Therapy with Temozolomide and Pembrolizumab in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 15C01, NCI-2015-00736, 3475-168, 51483, STU00200883, NCT02530502
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Combination Chemotherapy with or without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients with Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, CR00018679, CR00021317, CR00022743, CR00023930, eIRB #922, MR00041590, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797
Start Over